Strides Pharma Science is currently trading at Rs. 312.10, up by 4.10 points or 1.33% from its previous closing of Rs. 308.00 on the BSE.
The scrip opened at Rs. 324.00 and has touched a high and low of Rs. 324.00 and Rs. 310.45 respectively. So far 10002 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 10 has touched a 52 week high of Rs. 547.35 on 14-Feb-2020 and a 52 week low of Rs. 271.00 on 20-Mar-2020.
Last one week high and low of the scrip stood at Rs. 346.40 and Rs. 274.00 respectively. The current market cap of the company is Rs. 2807.88 crore.
The promoters holding in the company stood at 31.28%, while Institutions and Non-Institutions held 47.24% and 21.48% respectively.
Strides Pharma Science has received the Establishment Inspection Report (EIR) for the inspection conducted by the USFDA in January 2020 at Company’s flagship facility KRS Gardens, Bangalore. The inspection was related to specific Extended Release applications made from the site. Receipt of EIR confirms the successful closure of the inspections.
The flagship facility in Bangalore is the largest manufacturing facility for the company with capabilities to produce finished dosage formulation products across multiple dosage formats including tablet, capsules, ointments, creams and liquids.
Strides Pharma Science (Formerly Strides Shasun) is a pharmaceutical company with a major focus on development and manufacture of IP-led niche finished dosage formulations. It is also among the world’s largest manufacturers of soft gelatin capsules.